<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611077</url>
  </required_header>
  <id_info>
    <org_study_id>Sevicontrol-2</org_study_id>
    <nct_id>NCT01611077</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg</brief_title>
  <acronym>Sevicontrol-2</acronym>
  <official_title>Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to find out if a treatment with a new combination of two different
      antihypertensive drugs (olmesartan and amlodipine) in one tablet in patients with moderately
      elevated blood pressure is more effective than treatment with just one substance
      (candesartan). All antihypertensive treatment will be ceased for two weeks to achieve
      comparable baseline conditions. Treatment is then started with the single substance. After
      six weeks, therapy is changed to another single substance and after a further six weeks, to
      the fixed combination tablet. Blood pressure is determined by office measurements taken by
      the doctor and via long-term ambulatory blood pressure monitoring (ABPM). Participants may be
      male or female and must be over 18 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SEVICONTROL-2:

      Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed
      combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate
      hypertension - an open phase IV trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic daytime mean ABPM (long-term ambulatory blood pressure monitoring) values</measure>
    <time_frame>ABPM will be performed after 6 weeks treatment with each of the different therapy regimes.</time_frame>
    <description>After six weeks therapy with a monotherapy with olmesartan 40 mg and further six weeks treatment with a fixed combination of olmesartan 40 mg and amlodipine 10 mg compared to previous monotherapy with candesartan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systolic/diastolic office blood pressure and mean values (night-time and 24 hr for systolic bp and day-time, night-time and 24 hr for diastolic bp)</measure>
    <time_frame>after 6 and 12 weeks</time_frame>
    <description>from candesartan to olmesartan 40 mg and then to a fixed combination of olmesartan 40 mg and amlodipine 10 mg.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan cilexetil</intervention_name>
    <description>Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>Switch to olmesartan 40 mg tablets once daily for 42 days,</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Olmetec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan/amlodipine</intervention_name>
    <description>then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Sevikar (r)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients &gt;= 18 years of age

          -  essential hypertension, i. e. systolic office bp &gt;= 140 mmHg for pre-treated patients
             or &gt;= 160 mmHg for untreated patients at screening visit and &gt;= 160 mmHg at end of
             wash-out

          -  signed IC

        Exclusion Criteria:

          -  systolic office bp &gt; 180 mm Hg at screening visit

          -  known hypertensive retinopathy GIII or IV

          -  recent (&lt; 4 weeks ago) myocardial infarction or indication for coronary or peripheral
             revascularisation

          -  type I diabetes or poorly controlled (HbA1c &gt;= 8) type II diabetes

          -  chronic heart failure NYHA III or IV

          -  prior stroke or TIA

          -  creatinine clearance &lt; 60 ml/min or condition after kidney transplant

          -  moderately or severely impaired liver function (ALT or AST or bilirubin more than
             double normal value)

          -  women of childbearing potential without highly effective contraception, pregnant or
             breastfeeding women

          -  concomitant therapy with lithium

          -  hemodynamically relevant mitral or aortic valve stenosis (&gt;= II°) or hypertrophic
             obstructive cardiomyopathy

          -  concomitant therapy with strong CYP3A4 inhibitors or inductors

          -  african patients

          -  concomitant severe psychiatric condition that might impair proper intake of study
             medication

          -  life expectancy &lt; 6 months

          -  night shift workers

          -  known other mandatory indication for treatment with antihypertensive medications

          -  parallel participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Lüders, Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St.-Josefs-Hospital Cloppenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. Reimer</name>
      <address>
        <city>Anderbeck</city>
        <zip>38836</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Heinz</name>
      <address>
        <city>Bergisch-Gladbach</city>
        <zip>51429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Zemmrich</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Josefs-Hospital</name>
      <address>
        <city>Cloppenburg</city>
        <zip>49661</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Pohl</name>
      <address>
        <city>Dresden</city>
        <zip>01129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Koßler-Wiesweg</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Rövenich</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Strzata</name>
      <address>
        <city>Kapellendorf</city>
        <zip>99510</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Paschmionka</name>
      <address>
        <city>Leipzig</city>
        <zip>04316</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Pitule</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Loddo</name>
      <address>
        <city>Rastede</city>
        <zip>26180</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://dx.doi.org/10.1111/jch.12227</url>
    <description>Results Publication</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

